Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
ABERA | SPGR
Overview
Corporate Details
- ISIN(s):
- SE0015245097
- LEI:
- 549300IO3Q8IE2FDUS29
- Country:
- Sweden
- Address:
- BOX 1747, 751 47 Uppsala
- Website:
- https://aberabio.com/
Description
Abera Bioscience AB is a biotechnology company developing next-generation mucosal vaccines using its proprietary, modular Outer Membrane Vesicle (OMV) platform. This technology enables the rapid design and cost-effective, scalable production of vaccines delivered primarily via nasal spray. The company's approach aims to induce strong and durable mucosal and systemic immunity against infectious diseases. Its development pipeline includes a serotype-independent pneumococcal vaccine candidate preparing for Phase 1 clinical trials and a nasal influenza vaccine in preclinical development. The platform is designed for global health applications, with potential for powder formulations to reduce cold-chain dependency and improve accessibility.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Abera Bioscience AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abera Bioscience AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abera Bioscience AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
